logo
  

Baidu, Sanofi Ink License Deal To Integrate Baidu's Design Into Sanofi's Product Design Pipeline

AI company Baidu.com, Inc. (BIDU) and French drug major Sanofi (SNYNF,SNY) have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline.

Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses.

This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond Covid-19.

LinearDesign is a novel algorithm developed by Baidu researchers in 2020 specifically for mRNA sequence design. Experiments both in vitro and in vivo have demonstrated the effectiveness of LinearDesign in improving the stability and immunogenicity of Spike protein-encoding mRNA.

The LinearDesign program is part of Baidu's ongoing effort to develop innovative computational biology technology aiming to accelerate novel drug discovery.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Variety store chain Family Dollar is recalling around 38,300 units of beach loungers citing injury risk, the U.S. Consumer Product Safety Commission said. The recall involves beach lounge chairs with a white metal frame and either red or blue woven plastic fabric. The lounge chairs have a hang tag intended to be removed after purchase. Aerospace giant Boeing Co. (BA) on Wednesday reported fourth-quarter net loss attributable to Boeing shareholders of $4.16 billion or $7.02 per share, sharply narrower than $8.44 billion or $14.65 per share in the year-ago quarter. The 787 program recorded $3.5 billion pre-tax non-cash charge; focused... Telecom giant AT&T reported Wednesday a profit for the fourth quarter compared to a loss last year, primarily boosted by continuing customer growth in wireless, fiber and HBO Max, despite a 10 percent drop in revenues. Both adjusted earnings for the quarter and quarterly revenues also topped analysts' expectations. However, the company issued weak earnings and sales growth outlook for fiscal 2022.
Follow RTT